1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Clinical Research Network on Antimicrobial Resistance is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). This program aims to design, implement, and manage clinical research addressing key clinical questions in Antimicrobial Resistance (AMR), focusing on bacterial and fungal infections.
Areas of emphasis include clinical testing of new antibiotics and other treatments, optimizing existing antibiotic use, evaluating novel diagnostic tests, and mentoring future AMR clinical researchers.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Research Initiatives on Antimicrobial Resistance | NIAID: National Institute of Allergy and Infectious Diseases Resources for Researchers Division of Intramural Research Labs Research at Vaccine Research Center Intramural Scientist & Clinician Directory Research Rules & Policies Allergy, Immunology & Transplantation Resources for Researchers Antimicrobial (Drug) Resistance Antimicrobial Resistance Threats Information for Researchers Risk Factors & Prevention Research Immune Tolerance Processes Disease-Specific Research Information for Researchers Autoimmune Lymphoproliferative Syndrome (ALPS) Basic & Preclinical Research Information for Researchers Information for Researchers Shiga Toxin-Producing E.
coli (STEC) Researching Ebola in Africa Information for Researchers Information for Researchers Why Food Allergy is a Priority for NIAID Characterizing Food Allergy & Addressing Related Disorders Information for Researchers Diagnosis & Management Guidelines Disease-Specific Research Information for Researchers Genomics & Advanced Technologies Pathogen-Based Initiatives Information for Researchers Information for Researchers Group A Streptococcal Infections Disease-Specific Research Information for Researchers Overview of the Immune System Features of an Immune Response Information for Researchers Information for Researchers Leprosy (Hansen's Disease) How NIAID is Addressing Lyme Disease Information for Researchers Parasite, Mosquito & Human Host Prevention, Treatment & Control Strategies Strategic Partnerships & Research Capacity Information for Researchers Information for Researchers Neglected Tropical Diseases Information for Researchers Translational & Clinical Research Cross-cutting Preparedness Molecular & Genetic Research Primary Immune Deficiency Diseases (PIDDs) Information for Researchers Animal Prion Diseases and Humans Information for Researchers Respiratory Syncytial Virus (RSV) Schistosomiasis (Bilharzia) Research in Endemic Regions Sexually Transmitted Infections (STIs) NIAID's Research Approach Information for Researchers Disease-Specific Research Information for Researchers Information for Researchers Disease-Specific Vaccines Information for Researchers Translational & Clinical Research Information for Researchers Biology, Genetics & Clinical Research NIAID's Approach to Women's Health Research Sex-Specific Health Challenges Facing Women Biennial Report (FY 2019-2020) Information for Researchers Why NIAID Is Researching Zika Virus Information for Researchers Find a Funding Opportunity Opportunities & Announcements NIAID Research Priorities Plan Your Budget & Personnel Additional Application Elements Research with Special Considerations After You Submit an Application Funding Policies and Considerations Understand the Review Process Respond to Pre-Award Requests Negotiation & Initial Award Become a Healthy Volunteer Participant's Guide to Clinical Trials HIV and Emerging Infectious Diseases Laboratory of Infectious Diseases Primary Immune Deficiency Clinic Vaccine Research Center Clinical Studies Fill Out the Volunteer Form Q&A: Vaccine Clinical Studies Vaccine Clinical Studies Safeguards Clinical Trial Publications NIAID-Funded Research News Division of Allergy, Immunology, and Transplantation Division of Microbiology and Infectious Diseases Division of Extramural Activities Division of Clinical Research Division of Intramural Research Dr. Joseph J.
Kinyoun: Father of the NIH Dr. Joseph Kinyoun The Indispensable Forgotten Man Dr. Joseph Kinyoun: Selected Bibliography NIAID 60th Anniversary Timeline Research Training at NIAID Campuses Grant Programs that NIAID Funds AIDS Research Advisory Committee AIDS Vaccine Research Subcommittee Board of Scientific Counselors Members Advisory and Peer Review Committees Autoimmune Diseases Committee Website Policies and Notices External Link Icon and Disclaimers Freedom of Information Act (FOIA) Voluntarily Submitted Information Research Initiatives on Antimicrobial Resistance NIAID research initiatives focused exclusively or in part on antimicrobial resistance — listed by fiscal year (FY) in which awards will be made.
(You can use the NIH RePORTER to retrieve details about projects funded by these initiatives.)
2026 NIAID DMID Omnibus Broad Agency Announcement Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) (P01 Clinical Trial Not Allowed) Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trial Not Allowed) Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed) Centers of Excellence for Translational Research 2024 NIAID Omnibus Broad Agency Announcement Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antibiotic-Resistant Gram-Negative Bacteria 2023 NIAID Omnibus Broad Agency Announcement Host Immunity and Novel Immunization Strategies for Clostridioides difficile Infection (CDI) (U19, Clinical Trial Not Allowed) 2022 NIAID Omnibus Broad Agency Announcement Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi Partnerships for Rapid Diagnostics and Phenotypic Antibacterial Susceptibility Testing for Bacteremia or Hospital Acquired Pneumonia Syphilis Specimen Collection DMID Omnibus Broad Agency Announcement Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21) Chemistry Center for Combatting Antibiotic-Resistant Bacteria Combatting Antibiotic-Resistant Bacteria Interdisciplinary Research Units (U19) Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections and Emerging Infectious Diseases Leadership Group for a Clinical Research Network on Antibacterial Resistance (UM1) Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections and Emerging Infectious Diseases Centers of Excellence for Translational Research (U19) Partnerships for Countermeasures against Select Pathogens (R01) Sexually Transmitted Infections (STI) Cooperative Research Centers (U19) Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antimicrobial-Resistant Gram-Negative Bacteria (R01) Partnerships for Development of Clinically Useful Diagnostics for Antimicrobial- Resistant Bacteria Partnerships for the Development of Vaccines and Immunoprophylactics Targeting Mulitple Antimicrobial-Resistant Bacteria Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21) Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01) Partnerships for Countermeasures Against Select Pathogens (R01) Development of Therapeutic Products for Biodefense and Emerging Infectious Diseases Partnerships for the Development of Host-Targeted Therapeutics to Limit Antibacterial Resistance Non-Traditional Therapeutics that Limit Antibacterial Resistance Systems Biology and Antibacterial Resistance Development of Novel Therapeutics for Select Anaerobic Protozoa Development of Novel Therapeutics for Select Pathogens Partnerships for Diagnostics to Address Antimicrobial Resistance of Select Bacterial Pathogens Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases Targeting Therapeutics Development to Relieve Bottlenecks Centers of Excellence for Translational Research Drug Target Development and Validation for Antimicrobial Resistant Pathogens Leadership Group for a Clinical Research Network on Antibacterial Resistance Partnerships for Biodefense Pharmacological Approaches to Evaluating Drug Regimens to Address Antimicrobial Resistance Sexually Transmitted Infections Cooperative Research Centers Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases Partnerships for Development of Therapeutics and Diagnostics for Biodefense Partnerships for Interventions to Treat Chronic, Persistent and Latent Infections Sexually Transmitted Infections Clinical Trials Group Chemical Approaches to Target Validation for Drug Resistant Pathogens Targeting Resistance in Select Gram-Negative Pathogens Development of Therapeutics for Biodefense Partnerships for Biodefense Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (R01) Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (SBIR) Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance Content last reviewed on January 27, 2026
According to the current listing, eligibility includes: Open to various organizations including non-profits, private and public institutions of higher education, small businesses, for-profit organizations, and city, township, and special district governments. Confirm the full requirements in the official notice before applying.
The current listing shows $15,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Clinical Research Network on Antimicrobial Resistance are due September 29, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Clinical Research Network on Antimicrobial Resistance is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article